Abstract
OBJECTIVES: This study aims to determine the Turkish validity and reliability of the Composite Autonomic Symptom Score (COMPASS-31) in patients with fibromyalgia. PATIENTS AND METHODS: The study included 117 patients (113 females, 4 males; mean age: 43.0±11.0 years; range, 20 to 61 years) diagnosed with fibromyalgia between November 2021 and February 2023. The COMPASS-31, Revised Fibromyalgia Impact Questionnaire (FIQR), and the 36-item Short-Form Health Survey (SF-36) were used to collect data. The reliability of the scale was tested with internal consistency and test-retest reliability, and the validity was determined with construct validity. For test-retest reliability, 31 individuals (27 females, 4 males; mean age: 42.0±10.0 years; range, 21 to 60 years) were reassessed after one week. To establish the construct validity of COMPASS-31, its correlation with FIQR and SF-36 was assessed. RESULTS: Cronbach's alpha value was 0.912, and the intraclass correlation coefficient was 0.838, indicating high reliability and internal consistency. According to the construct validity analysis, COMPASS-31 showed a good positive correlation with FIQR (r=0.451, p<0.001), and good negative correlations were observed between COMPASS-31 and vitality, mental health, and general health subscales of SF-36 (r=-0.402, p>0.001; r=-0.404, p<0.001; r=-0.455, p<0.001). CONCLUSION: The Turkish version of the COMPASS-31 is valid and reliable to assess autonomic symptoms in patients with fibromyalgia.